BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 31354710)

  • 1. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote
    Jahnke S; Schmid H; Secker KA; Einhaus J; Duerr-Stoerzer S; Keppeler H; Schober-Melms I; Baur R; Schumm M; Handgretinger R; Bethge W; Kanz L; Schneidawind C; Schneidawind D
    Front Immunol; 2019; 10():1542. PubMed ID: 31354710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
    Michallet AS; Nicolini F; Michallet M
    Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.
    Rubio MT; Moreira-Teixeira L; Bachy E; BouilliƩ M; Milpied P; Coman T; Suarez F; Marcais A; Sibon D; Buzyn A; Caillat-Zucman S; Cavazzana-Calvo M; Varet B; Dy M; Hermine O; Leite-de-Moraes M
    Blood; 2012 Sep; 120(10):2144-54. PubMed ID: 22730537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.
    Burt RK; Drobyski WR; Seregina T; Traynor A; Oyama Y; Keever-Taylor C; Stefka J; Kuzel TM; Brush M; Rodriquez J; Burns W; Tennant L; Link C
    Exp Hematol; 2003 Oct; 31(10):903-10. PubMed ID: 14550806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.
    Luznik L; Fuchs EJ
    Cancer Control; 2002; 9(2):123-37. PubMed ID: 11965233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies.
    Dellabona P; Casorati G; de Lalla C; Montagna D; Locatelli F
    Clin Immunol; 2011 Aug; 140(2):152-9. PubMed ID: 21185785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients.
    Schneidawind C; Jahnke S; Schober-Melms I; Schumm M; Handgretinger R; Faul C; Kanz L; Bethge W; Schneidawind D
    Br J Haematol; 2019 Jul; 186(1):60-71. PubMed ID: 30916396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
    Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
    Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of invariant NKT cells in allogeneic hematopoietic stem cell transplantation.
    Karadimitris A; Chaidos A
    Crit Rev Immunol; 2012; 32(2):157-71. PubMed ID: 23216613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
    Ho VT; Kim HT; Kao G; Cutler C; Levine J; Rosenblatt J; Joyce R; Antin JH; Soiffer RJ; Ritz J; Avigan D; Alyea EP
    Am J Hematol; 2014 Dec; 89(12):1092-6. PubMed ID: 25132538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.
    Schmid H; Schneidawind C; Jahnke S; Kettemann F; Secker KA; Duerr-Stoerzer S; Keppeler H; Kanz L; Savage PB; Schneidawind D
    Front Immunol; 2018; 9():1817. PubMed ID: 30127790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression.
    Guan P; Bassiri H; Patel NP; Nichols KE; Das R
    Bone Marrow Transplant; 2016 May; 51(5):629-37. PubMed ID: 26878658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Baron F; Beguin Y
    Biol Blood Marrow Transplant; 2002; 8(7):351-9. PubMed ID: 12171481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
    Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
    Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.